CStone Pharmaceuticals
2616.HK
HKD5.57 -1.76%
Exchange: HKSE | Sector: Healthcare | Industry: Biotechnology
Q3 2024
Published: Sep 30, 2024

Earnings Highlights

  • Revenue of $76.52M down 24.4% year-over-year
  • EPS of $-0.04 increased by 32.4% from previous year
  • Gross margin of 44.5%
  • Net income of -53.45M
  • "N/A" -
2616.HK
Company 2616.HK

Executive Summary

CStone delivered QQ3 2024 revenue of CNY 76.52 million, down 24.38% year over year and 39.79% quarter over quarter, while continuing to invest heavily in R&D and commercialization activities. The company posted a gross margin of 44.5% but reported a substantial operating loss (EBITDA and net income negative by large margins), driven by elevated operating expenses (R&D and SG&A vs. revenue). The quarterly cash burn from operations amounted to CNY 78.02 million, financed by a solid liquidity position from cash and short-term investments totaling roughly CNY 719.88 million, yielding a net cash position of about CNY βˆ’31.96 million (net debt negative). The balance sheet shows a prudent liquidity cushion with a current ratio of 1.60 and a cash ratio of 0.57, while inventory remained elevated (CNY 286.10 million) with high days‑of‑inventory (606.46 days) and days‑sales outstanding (98.71 days), signaling ongoing pipeline development and manufacturing scale-up. Net income decline remained negative, but the loss narrowed YoY as the business progresses its pipeline toward potential future revenue catalysts. Looking ahead, near-term performance hinges on pipeline milestones, potential regulatory approvals, and any strategic collaborations that could monetize assets or de-risk development costs.

Key Performance Indicators

Revenue
Decreasing
76.52M
QoQ: -39.79% | YoY: -24.38%
Gross Profit
Decreasing
34.06M
44.51% margin
QoQ: -60.40% | YoY: -54.84%
Operating Income
Increasing
-51.21M
QoQ: -2 698.44% | YoY: 70.87%
Net Income
Increasing
-53.45M
QoQ: -780.97% | YoY: 32.34%
EPS
Increasing
-0.04
QoQ: -938.00% | YoY: 32.42%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 24.73 -0.10 -67.7% View
Q1 2025 24.73 -0.10 -80.5% View
Q4 2024 76.52 -0.04 -24.4% View
Q3 2024 76.52 -0.04 -24.4% View